282 related articles for article (PubMed ID: 28860412)
21. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
22. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
23. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
24. Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
Hwang GY; Baek DW; Cho HJ; Lee SJ; Chae YS; Kang BW; Lee IH; Kim JG; Seo AN; Bae HI; Park KB; Park JY; Kwon OK; Lee SS; Chung HY
Anticancer Res; 2018 May; 38(5):3151-3156. PubMed ID: 29715156
[TBL] [Abstract][Full Text] [Related]
25. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
27. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
[TBL] [Abstract][Full Text] [Related]
28. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Zhang YF; Yu YF; Lu S
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy beyond second-line in advanced gastric cancer.
Kim SM; Park SH
World J Gastroenterol; 2015 Aug; 21(29):8811-6. PubMed ID: 26269670
[TBL] [Abstract][Full Text] [Related]
32. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer.
Zhou K; Wen F; Zhang P; Zhou J; Chen H; Zheng H; Yang Y; Li Q
Clin Transl Oncol; 2017 Sep; 19(9):1117-1124. PubMed ID: 28353006
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
35. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study.
Wang Y; Chen Y; Yin H; Gu X; Shi Y; Dai G
Cancer Med; 2018 Apr; 7(4):997-1005. PubMed ID: 29532995
[TBL] [Abstract][Full Text] [Related]
36. Second-line chemotherapy for advanced gastric cancer in Korea.
Baek SK; Kim SY; Jeong JH; Cho KS; Yoon HJ
Gastric Cancer; 2012 Oct; 15(4):345-54. PubMed ID: 22410800
[TBL] [Abstract][Full Text] [Related]
37. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Bonotto M; Gerratana L; Iacono D; Minisini AM; Rihawi K; Fasola G; Puglisi F
Oncologist; 2015 Jul; 20(7):719-24. PubMed ID: 26018662
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Kwon HJ; Park MI; Park SJ; Moon W; Kim SE; Lee HW; Choi YJ; Kim JH
Korean J Gastroenterol; 2015 Jul; 66(1):10-6. PubMed ID: 26194124
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.
Battisti NML; Okonji D; Manickavasagar T; Mohammed K; Allen M; Ring A
Breast; 2018 Aug; 40():60-66. PubMed ID: 29698926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
